Browsing English Journal Articles (Peer Reviewed) by Authors
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.Keefe, S M; Hoffman-Censits, J; Cohen, R B; Mamtani, R; Heitjan, D; Eliasof, S; Nixon, A; Turnbull, B; Garmey, E G; Gunnarsson, O; et al. (Oxford Univ Press, 2016-08)Anti-angiogenic therapies are effective in metastatic renal cell carcinoma (mRCC), but resistance is inevitable. A dual-inhibition strategy focused on hypoxia-inducible factor (HIF) is hypothesized to be active in this refractory setting. CRLX101 is an investigational camptothecin-containing nanoparticle-drug conjugate (NDC), which durably inhibits HIF1α and HIF2α in preclinical models and in gastric cancer patients. Synergy was observed in the preclinical setting when combining this NDC and anti-angiogenic agents, including bevacizumab.